*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Shanghai Conant Optical Co., Ltd.**
**上海康耐特光學科技集團股份有限公司**
*(A joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock Code: 2276)**

# VOLUNTARY ANNOUNCEMENT
# 2026 & 2027 H-SHARE REPURCHASE PROGRAMME

Reference is made to: (i) the circular for the annual general meeting of Shanghai Conant Optical Co., Ltd. (the "**Company**") dated 28 April 2026 (the "**2025 AGM Circular**"); and (ii) the Company's poll results announcement dated 11 June 2026. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2025 AGM Circular.

On 11 June 2026, the Company held its 2025 AGM, at which a resolution to grant the Board a general mandate (the "**General Mandate**") to repurchase (the "**General Mandate to Repurchase Shares**") H-Share(s) ("**H-Share(s)**") was considered and approved by the Shareholders.

As disclosed in the Company's announcement dated 8 April 2026 and 15 June 2026, the 2026 April H-Share Repurchase Programme was completed on 5 June 2026. At the 19th meeting of the second session of the Board held on 5 November 2026, the Board considered and approved the "Proposal Regarding the 2026 & 2027 H-Share Repurchase Plan". To further safeguard the interests of the Shareholders and enhance investor confidence, pursuant to (i) the General Mandate, and (ii) the General Mandate to Repurchase Shares, the Board has approved another H-Share repurchase plan with a total repurchase amount not exceeding HK$400 million (the "**2026 & 2027 H-Share Repurchase Programme**"), the specific details of which are as follows:

## PURPOSE AND USE OF THE 2026 & 2027 H-SHARE REPURCHASE PROGRAMME

Based on our firm confidence in the Company's future prospects and our strong belief in the Company's value, and in order to further protect the Shareholders' interests and enhance investor confidence, the Company intends to repurchase its H-Shares after comprehensively considering its business prospects, operating performance, financial condition, future profitability, and the recent performance of the Company's H-Shares in the secondary market.

## TOTAL AMOUNT OF FUNDS AND SOURCES OF FUNDS TO BE USED FOR THE 2026 & 2027 H-SHARE REPURCHASE PROGRAMME

The total amount of funds to be used for the 2026 & 2027 H-Share Repurchase Programme will not exceed HK$400 million (the "**Maximum Limit**"). The 2026 & 2027 H-Share Repurchase Programme will be financed by the Company's internal cash, and other funds permitted under applicable laws and regulations. If the repurchase is funded by the cash held in onshore accounts, the Company will arrange for its owned foreign currency funds or the funds to be transferred to offshore through foreign exchange purchases, and can only be finalized after obtaining relevant approval from the State Administration of Foreign Exchange.

## REPURCHASE PRICE

Pursuant to the Listing Rules, the daily repurchase price of H-Shares shall not exceed 5% or more of the average closing price of the H-Shares over the five trading days immediately preceding the repurchase date, while the specific price will depend on the prevailing market conditions.

## NUMBER OF H-SHARES TO BE REPURCHASED

The number of H-Shares to be repurchased shall not exceed 10% of the total number of issued H-Shares (excluding treasury H-Shares) as of the date of 2025 AGM, i.e., 49,826,980 H-Shares, which was approved under the General Mandate to Repurchase Shares.

The Board does not intend to exercise the General Mandate to the extent that the number of H-Shares held by the public falls below the minimum percentage required by the Stock Exchange, or to the extent that it would result in an obligation to make a mandatory general offer to the Shareholders pursuant to Rules 26 and 32 of the Hong Kong Code on Takeovers and Mergers. Based on the above considerations, as at the date of this announcement, the number of H-Shares to be repurchased under the 2026 & 2027 H-Share Repurchase Programme is not expected to exceed 14,404,200 H-Shares.

## TERM OF THE 2026 & 2027 H-SHARE REPURCHASE PROGRAMME

The term of the 2026 & 2027 H-Share Repurchase Programme shall be valid from 12 November 2026 and shall continue until whichever is the earliest of:

1) the total amount of funds used under the 2026 & 2027 H-Share Repurchase Programme reaches the Maximum Limit;

2) any other date the Board approved and considered the termination of the 2026 & 2027 H-Share Repurchase Programme to be appropriate by passing such relevant resolution; or

3) the conclusion of the next annual general meeting of the Company.

No repurchase of H-Shares has been made under the 2026 & 2027 H-Share Repurchase Programme as at the date of this announcement. After the completion of the 2026 & 2027 H-Share Repurchase Programme, the Company will consider H-Share repurchase plans based on corporate strategies and prevailing market conditions on a regular basis.

## ARRANGEMENTS FOLLOWING THE REPURCHASE OF H-SHARES

The H-Shares repurchased under the 2026 & 2027 H-Share Repurchase Programme will be held as treasury H-Shares and disposed of in accordance with the Listing Rules, the Articles of Association, and any subsequent authorizations required. Specifically, the Company will transfer (including by sale on the secondary market) or cancel such repurchased H-Shares within three years after the completion of the repurchase under the 2026 & 2027 H-Share Repurchase Programme; and make the publication of the repurchase results announcement.

Should the Company intend to cancel the repurchased H-Shares in the future, it will strictly comply with the relevant decision-making and announcement procedures regarding capital reduction as stipulated in the Company Law of the People's Republic of China, the Articles of Association, the Listing Rules, and other applicable laws and regulations.

## SPECIFIC AUTHORIZATION TO THE MANAGEMENT TO HANDLE MATTERS RELATED TO THE 2026 & 2027 H-SHARE REPURCHASE PROGRAMME

To ensure the smooth implementation of the 2026 & 2027 H-Share Repurchase Programme, the Board authorizes the Company's management to handle matters relating to the H-Share repurchase, including but not limited to, determining at its discretion during the repurchase term and in accordance with the 2026 & 2027 H-Share Repurchase Programme, the timing, price, and quantity of H-Shares to be repurchased, as well as handling other matters relating to the H-Share repurchase.

The foregoing authorization shall take effect from the date of its approval by the Board and shall remain in effect until the matters covered by such authorization have been fully completed.

## RISK REMINDERS REGARDING THE 2026 & 2027 H-SHARE SHARE REPURCHASE PROGRAMME

The Shareholders and potential investors of the Company are advised that the H-Share repurchase will be subject to market conditions and must comply with applicable laws and regulations. Pursuant to the Board's authorization, the Company will make repurchase decisions and implement them at its discretion during the repurchase term. The Company does not guarantee the timing, quantity, or price of any H-Share repurchases. The Shareholders and potential investors of the Company are advised to exercise caution when trading the Company's securities.

By Order of the Board
**Shanghai Conant Optical Co., Ltd.**
**Fei Zhengxiang**
*Executive Director and Chairman of the Board*

Hong Kong, 12 November 2026

*As at the date of this announcement, the Board comprises Mr. Fei Zhengxiang, Mr. Zheng Yuhong, Mr. Xia Guoping, Mr. Chen Junhua, Mr. Wang Chuanbao and Ms. Cao Xue as executive Directors; Ms. Zhao Xiaoyun and Mr. Tian Kehan as non-executive Directors; and Dr. Xiao Fei, Mr. Chen Yi, Dr. Wu Ying and Mr. Jin Yiting as independent non-executive Directors.*